Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947750 · ClinicalTrials.gov registry record · Phase 2
Neurovascular Transduction During Exercise in Chronic Kidney Disease
A Phase 2 study of Renal Insufficiency, Chronic, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT02947750 is a Phase 2 study of Renal Insufficiency, Chronic that is actively recruiting participants, run by Emory University. The registered enrollment target is 150 participants, below the 639-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT02947750, a Phase 2 study of Renal Insufficiency, Chronic, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.
Conditions Studied
Interventions
- OTHER Exercise training
- DRUG 6R-BH4
- OTHER 6R-BH4 placebo
- DIETARY_SUPPLEMENT Folic acid
- OTHER Stretching
Study Locations (3)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University Hospital - Atlanta
- Atlanta VA Health Care System - Decatur
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2016-10 |
| Est. Completion | 2026-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947750
The ClinicalTrials.gov registry entry for NCT02947750 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 14 other Renal Insufficiency, Chronic trials with a reported enrollment target (77% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Insufficiency, Chronic appearing as the primary indexed condition, and to 5 interventions - of which Exercise training is the first listed.
NCT02947750 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02947750 about?
NCT02947750 is a clinical study titled "Neurovascular Transduction During Exercise in Chronic Kidney Disease". The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test ...
What is the current status of trial NCT02947750?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2016-10. Estimated completion is 2026-01.
What conditions does trial NCT02947750 study?
This clinical trial studies the following conditions: Renal Insufficiency, Chronic.
What interventions are being tested in trial NCT02947750?
The interventions under investigation include: Exercise training (OTHER), 6R-BH4 (DRUG), 6R-BH4 placebo (OTHER), Folic acid (DIETARY_SUPPLEMENT), Stretching (OTHER).
Who is sponsoring clinical trial NCT02947750?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02947750 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ascertain the Optimal Starting Dose of Mircera Given Subcutaneously for Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.
COMPLETED · Phase 2
-
Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934
COMPLETED · Phase 2
-
Transformative Research in Diabetic Nephropathy 2.0
RECRUITING
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
Penn Produce Prescription and Chronic Kidney Disease Study
ACTIVE NOT RECRUITING · NA
-
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.